

1 **SARS-CoV-2 Neutralization in Commercial Lots of Plasma-derived Immunoglobulin**

2

3 Volk, Andreas^{1+#}; Covini-Souris, Caroline^{2#}; Kuehnel, Denis¹; De Mey, Christian³, Römisch, Jürgen^{2*}; Schmidt,

4 Torben^{1*}

5 1: Octapharma Biopharmaceuticals[®] GmbH, Virus and Prion Validation, Frankfurt, Germany

6 2: Octapharma[®] Pharmazeutika Produktionsgesellschaft m.b.H., R&D Plasma, Vienna, Austria

7 3: ACPS-Network GmbH, Wiesbaden, Germany

8 #: Both authors contributed equally

9 *: Both authors contributed equally

10 +: Please address correspondence to: andreas.volk@octapharma.com

11

12

13

1 **Abstract**

2 **Introduction**

3 Patients suffering from primary or secondary immunodeficiency face times of increased insecurity and
4 discomfort in the light of the raging Covid-19 pandemic, not knowing if and to what extend their comorbidities
5 impact a potential Covid-19 course of disease. Furthermore, recently available vaccination options might not be
6 amenable or effective for all patients of this heterogeneous population. Therefore, these patients often rely on
7 passive immunization with plasma-derived, intravenous or subcutaneous immunoglobulin (IVIG/SCIG).

8 Whether the ongoing Covid-19 pandemic and/or the progress in vaccination programs lead to increased and
9 potentially protective titers in plasma-derived immunoglobulins (Ig) indicated e.g. for humoral
10 immunodeficiency remains a pressing question for this patient population.

11 **Purpose**

12 Here we investigated SARS-CoV-2 reactivity of US plasma-derived IVIG/SCIG products from the end of 2020
13 until 06/2021 as well as in convalescent plasma (CP) from 05/2020 to 08/2020.

14 **Methods**

15 Final containers of IVIG/SCIG and CP donations were analyzed by commercial ELISA for SARS-CoV-2 S1-
16 RBD IgG as well as microneutralization assay using a patient-derived SARS-CoV-2 (D614G) isolate.
17 Neutralization capacities of 313 plasma single donations and 119 plasma-derived IVIG/SCIG lots were
18 determined. Results obtained from both analytical methods were normalized against the international WHO
19 standard. Finally, based on dense pharmacokinetic profiles of an IVIG preparation from previously published
20 investigations, possible steady-state plasma levels of SARS-CoV-2 neutralization capacities were approximated
21 based on currently measured anti-SARS-CoV-2 potencies in IVIG/SCIG preparations.

22 **Results**

23 CP donations presented with a high variability with regards to anti-SARS-reactivity in ELISA as well as in
24 neutralization testing. While approximately 50% of convalescent donations were none/low neutralizing,
25 approximately 10% were at or above 1000 IU/ml.

26 IVIG/SCIG lots derived from pre-pandemic plasma donations did not show neutralizing capacities of SARS-
27 CoV-2. Lots produced between 12/2020 and 06/2021, entailing plasma donations after emergence of SARS-

1 CoV-2 showed a rapid and constant increase in anti-SARS-CoV-2 reactivity and neutralization capacity over
2 time. Neutralization capacity increased from a mean of 20 IU/ml in 12/2020 to 505 IU/ml in 06/2021, while lot-
3 to-lot variability was substantial.

4 Pharmacokinetic (PK) extrapolations based on non-compartmental superposition principles using steady-state
5 reference profiles from previously published PK investigations on IVIG in PID, yielded potential steady-state
6 trough plasma levels of 16 IU/ml based on the average final container concentration from 05/2021 with
7 216 IU/ml. Maximum extrapolated trough levels could reach 64 IU/ml based on the latest maximal final
8 container potency tested in 06/2021.

9 **Conclusions**

10 SARS-CoV-2 reactivity and neutralization capacity in IVIG/SCIG produced from US plasma rapidly and in part
11 exponentially increased in the first half of 2021. The observed increase of final container potencies is likely
12 trailing the serological status of the US donor population in terms of Covid-19 convalescence and vaccination by
13 at least 5 months due to production lead times and should in principle continue at least until fall 2021. In
14 summary, the data support rapidly increasing levels of SARS-COV-2 antibodies in IVIG/SCIG products
15 implicating that a certain level of protection could be possible against COVID-19 for regularly substituted
16 PID/SID patients. Nevertheless, more research to confirm, which plasma levels are needed for protection against
17 SARS-CoV-2 infection of immune-compromised patients is still needed.

18 **Key Points**

- 19 • Patients with humoral immunodeficiency rely on plasma-derived immunoglobulin for passive
20 immunization against numerous pathogens.
- 21 • Plasma-derived immunoglobulins contain increasing SARS-CoV-2 neutralization capacities with
22 ongoing Covid-19 pandemic and vaccination campaigns.
- 23 • Plasma-derived immunoglobulin in prophylactic use for immunodeficient patients could potentially aid
24 against SARS-CoV-2 infection in the future.

25

26 **Keywords**

27 Convalescent Plasma, Covid-19, ELISA, immunoglobulin, IVIG, neutralization, passive immunization, PID,
28 SID, SARS, SARS-CoV-2, SCIG.

1 1. Introduction

2 The principle of passive immunization, i.e. the infusion of antibodies (ab) from a healthy immunized or
3 convalescent donor to a patient not mounting an own, active immune response, is a long-standing treatment
4 option for infectious diseases and has been first applied by Emil von Behring, who received the first ever Nobel
5 prize in 1901 for the serum therapy on Diphtheria [3]. Passive immunization refers to ab transfer by means of
6 recombinant monoclonal antibodies, plasma-derived intravenous or subcutaneous immunoglobulin (IVIG/SCIG)
7 or convalescent plasma (CP). In fact, CP therapy has faced a renaissance as possible treatment option in the
8 currently ongoing Covid-19 pandemic to bridge in mostly therapeutic settings while other therapeutics and
9 especially vaccines as protective measure were not yet available [4–6]. FDA granted emergency use
10 authorization for CP therapy in August 2020 and revised these guidance in March 2021 to use only higher titer
11 CP early in the course of disease [7]. However, for the therapeutic setting a meta-analysis by Peng et al.
12 identified a total of 243 studies published including 64 clinical trials on CP administration for prevention and
13 treatment of Covid-19 by April 2021 [8]. In brief, efficacy of CP therapy against Covid-19 as therapeutic has not
14 been shown univocally and remains a matter of debate and further clinical investigation [9–14]. In this course,
15 the criticality of early treatment with CP as well as required dose and specific ab titers of the donations are
16 discussed as part of relevant drivers for treatment success [13]. Likewise, the prophylactic use of CP has not
17 found broad application [8]. However, efficacious prophylaxis against disease using CP has been shown in a
18 hamster and macaque models [15–17]. Furthermore, recombinant monoclonal ab prophylaxis, clinical efficacy
19 has been shown supporting the notion that immunoglobulin G (IgG) molecules can prevent infection/Covid-19
20 [18, 19].

21 Active immunization of patients with primary immunodeficiencies (PID) as well as secondary
22 immunodeficiencies (SID), which in part manifest a lack or impeded humoral response have recently been
23 reported with encouraging findings [20, 21]. However, not all patients within this heterogeneous group are
24 amenable to vaccination or vaccination might not lead to immune protection [22, 23]. Furthermore, Covid-19
25 disease in this indication group has been reported to have both less [24] and more severe outcomes depending on
26 comorbidities and individual patient factors [25].

27 Regardless of the amenability of active vaccination and the potential disease outcome, passive immunization by
28 repeated injection of IVIG/SCIG for at least a part of this patient group is the standard of care for humoral
29 deficiency and has been ongoing prior to, during and after the SARS-CoV-2 pandemic [26–28]. IVIG/SCIG are
30 purified and concentrated immunoglobulin (Ig) preparations derived from pooled plasma donations [29, 30].

1 Therefore, the reactivity and neutralizing potency of these IgG pharmaceutical products are directly dependent
2 on the epidemiologic experience of the donor population [19–21].

3 It is thus of high interest - in the light of increasing seroconversion in the donor population - how currently
4 manufactured IVIG/SCIG can serve these immunodeficient patient groups in terms of protection against a
5 SARS-CoV-2 infection or impede disease severity of Covid-19. First reports of anti-SARS-CoV-2 reactivity and
6 neutralization capacities in commercially produced immunoglobulins have already been published [31–35].

7 To obtain an impression on how CP donations vary in terms of potency, we first investigated a selection of
8 Covid-19 CP donations from 05/2020 to 08/2020 for SARS-CoV-2 reactivity by use of commercially available
9 SARS-CoV-2 IgG ELISA and an inhouse established SARS-CoV-2 microneutralization assay under BSL-3
10 conditions to assess for actual neutralization capacity.

11 We furthermore analyzed commercial lots of immunoglobulin manufactured from 11/2020 to 06/2021 by
12 ELISA. A fraction of these lots was subsequently subjected to neutralization testing against actual SARS-CoV-2
13 virus.

14 Lastly, we performed calculations based on previous pharmacokinetic (PK) profiles of IVIG to obtain a first and
15 preliminary insight into possibly achievable steady-state plasma levels in patients regularly dosed with IVIG.

16

17

1 **2. Material and Methods**

2 **2.1. IVIG/SCIG**

3 Octagam[®] and Panzyga[®] are polyclonal IVIG- and Cutaquig[®] is a polyclonal SCIG product derived from
4 thousands of plasma donations. We tested lots prepared from US donations from 11/2020 to 06/2021. Octagam[®]
5 is available as 50 mg/ml and 100 mg/ml (5 and 10%) preparations, Cutaquig[®] is available in 165 mg/ml (16.5 %)
6 while Panzyga[®] is available in 100 mg/ml (10%) IgG concentration. All reported results were normalized to a
7 potency of 100 mg IgG/ml to remove bias from different formulations.

8

9 **2.2. Single donation of CP**

10 CP donations were collected from 05/2020 to 08/2020. Octapharma[®] invited donors to present proof of resolved
11 SARS-CoV-2 infection (either by positive diagnostic test or positive serological test) to be eligible to donate CP
12 after a deferral period of 14 days after either diagnostic test or symptom cessation, whatever applicable.

13

14 **2.3. SARS-CoV-2 ELISA kit**

15 The following ELISA kits were used for detection of SARS-CoV-2 IgG against receptor binding domain (RBD)
16 of spike protein S1: EI-2606-9601 G ELISA kit (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck,
17 Germany) for qualitative detection; QuantiVac EI-2606-9601-G ELISA (EUROIMMUN Medizinische
18 Labordiagnostika AG, Lübeck, Germany) for quantitative determination of IgG titers. Tests were performed as
19 instructed by the provider.

20 CP was stored frozen and thawed promptly before analysis. Samples were diluted with buffer solutions provided
21 in each ELISA kit. After qualitative detection, results were expressed as ab ratio.

22 Concentrated IVIG/SCIG lots were diluted using buffer solutions included in each ELISA kit. 5, 10 and -16.5 %
23 IgG preparations were tested in 3 dilution series ranging from 1:1 to 1:10. All samples were tested in 8 replicates.
24 Results were initially obtained in relative units (RU/ml) and were normalized against the First WHO International
25 Standard (NIBSC code: 20/136) in binding antibody units/ml (BAU/ml) as described by the test kit provider. All
26 quantitative results were normalized to 100 mg/ml IgG for comparison.

27

1 2.4. Cell culture

2 Vero cells (CCL-81, American Type Culture Collection) were cultured in RPMI-1640 medium (Sigma®),
3 supplemented with 10% foetal bovine serum (Sigma®) and 1% penicillin/streptomycin (Sigma®) at 37°C, 5% CO₂
4 in saturated humidity.

5

6 2.5. Virus

7 SARS-CoV-2 (Human 2019-nCoV ex China_BavPat1/2020_Germany ex China, GISAID ID: EPI_ISL_406862)
8 was kindly provided by Prof. Dr. Christian Drosten, Institute of Virology, Charité, Universitätsmedizin Berlin,
9 Germany [36].

10 All handling of virus was performed under BSL-3 conditions according to German law and regulations.

11 The virus was propagated on Vero cells established one day prior inoculation with 20 ml of 0.5 x 10⁵ cells /ml in
12 Vero culture medium (see above) in a T75 cell culture flask (Falcon®). Next day, the culture medium was removed
13 completely. Cells were inoculated with SARS-CoV-2 at a multiplicity of infection of 0.01 in a total of 5 ml virus
14 suspension. Cell inoculation was incubated for 1h at 37°C, 5% CO₂ in saturated humidity until an additional
15 volume of 20 ml Vero cell culture medium was added. Cells were maintained for 4-5 days and monitored for
16 development of cytopathic effect (CPE). Once a CPE of 50-70% was reached, supernatant was removed and
17 centrifuged to remove cellular debris (4°C, 15 min at 1500x g). The cell monolayer in the T75 culture flask was
18 frozen thrice in -80°C ultra-deep freezer for cell lysis. The flask was then rinsed thoroughly with the refrigerated
19 culture supernatant removed beforehand. After repeated centrifugation, suspension was 0.45 µm filtered, aliquoted
20 and stored in a -80°C ultra-deep freezer until use.

21

22 2.6. Standards and Reagents

23 2.6.1. Neutralization standards

24 WHO International Standard / First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human)
25 was obtained from National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire,
26 EN6 3qG, UK NIBSC code: 20/136. [1]. The internal standard has a rated potency of 1000 IU/ml or 1000 BAU/ml
27 depending on assay type, if reconstituted according to instructions.

28 Internal neutralization standard “V” was generated in-house at Octapharma® Virus and Prion Validation by pooling

1 a selection of CP samples. After pooling samples were aliquoted and kept frozen at -80°C until use. Standard was
2 diluted 1:40 initial dilution in 20% citrate dextrose (ACD, Sigma®) in Vero culture medium to avoid clotting.
3 Internal neutralization standard “O” was a high-titer single source plasma donation obtained from Octapharma
4 Plasma Inc.®, Charlotte, NC, USA. After thawing, the donation was aliquoted and kept frozen at
5 -80°C until use. Standard was diluted 1:40 initial dilution in 20% ACD in Vero culture medium to avoid clotting.

6

7 **2.7. Neutralization Testing**

8 Neutralization Testing (NT) was done in two microneutralization assay formats differing in sample dilution
9 schemes and -replicates. Both assays were not prospectively validated. In both, Vero cultures were prepared one
10 day prior assay conduct and seeded in 120 µl each per 96 well with 0.5×10^4 cells/ml (= 600 cells per well).

11 In the screening assay format, which was used in the CP donation testing, each plasma sample was thawed at 37°C
12 and initially diluted 1:40 with 20% citrate dextrose (ACD) in cell culture medium to avoid clotting. Subsequently,
13 samples were serially diluted 1:2-fold in six consecutive steps. Each of the four parallel dilutions was assayed once
14 for neutralization. The assay principle was adapted from Gauger & Vincent [37].

15 In the potency assay format deployed for final container testing, each sample was assayed in 3 independent dilution
16 series. After a first 1:10 dilution step, 10 consecutive 1:2 dilution steps were performed. Each dilution was assayed
17 in octuplicates, respectively. This assay format has been published earlier [32, 38].

18 In both assay versions, each sample dilution was subsequently challenged with an equal volume of virus
19 suspension, which had a titer of $3.0 \log_{10}$ TCID₅₀/ml. The virus titer was confirmed each working day by so-called
20 back titrations. A mean titer of n=5 titrations was determined (refer to section “virus titration”) to accurately
21 account for the actual viral load in the immune neutralization, which was used as normalizing factor to account for
22 potential inter-run variances.

23 In both formats, the neutralization reaction was incubated for 150 ± 15 min at 37°C in a CO₂ incubator at saturated
24 humidity. After the incubation period 100 µl of each replicate dilution was transferred onto a 96-well culture of
25 Vero cells (see above). Inoculated cultures were maintained for 7 days at 37°C, 5% CO₂ in saturated humidity. On
26 day 7, cultures were microscopically evaluated for the presence or absence of cytopathic effect by two independent
27 operators (four eyes-principle). Neutralization potency by means of dilution to achieve a 50% neutralization of
28 virus was calculated using Spearman-Kärber-based statistics [38].

29 In order to convert the identified NC50 dilution values into International units, the normalized (mean)

1 neutralization values of the sample were divided by the (mean) neutralization of the internal standard run along
2 the same experiment and then multiplied by the calibrated potency of the internal standard in international units.

3

4 **2.8. Virus titration**

5 On each day of neutralization, the virus stock used as challenge inoculum for neutralization studies was assessed
6 via repeated titration by means of Spearman-Kärber statistics [39]. For that, a serial 1:3 dilution of the virus stock
7 was prepared in 12 consecutive steps in Vero cell culture medium. Subsequently, 8x 100 µl of each dilution were
8 added to a 96-well plate containing Vero cultures established one day earlier as described above. Inoculated
9 cultures were maintained for 7 days at 37°C, 5% CO₂ in saturated humidity. On day 7, cultures were
10 microscopically evaluated for the presence or absence of cytopathic effect by two independent operators.

11

12 **2.9. PK Analysis**

13 Steady-state levels of IgG on 4-weekly dosing were approximated by superposition principles using baseline-
14 adjusted dose-normalized reference profiles from a previously published clinical trial (EudraCT 2009-011434-
15 10) that investigated the steady-state pharmacokinetics of IgG on 4-weekly repeated dosing of IVIG 10% in
16 patients with primary immunodeficiency syndrome [40]. The individual courses of total IgG were baseline-
17 adjusted, assuming that the baseline levels were residuals from previous dosing whilst endogenous levels were
18 negligible. In order to be able to pool the profiles across subjects, the baseline-adjusted profiles were dose-
19 normalized. The time courses of the median, 25th (P25), and 75th (P75) percentile levels of the baseline-adjusted
20 dose-normalized data were used as reference profiles. These reference profiles were expanded by linear/log-
21 linear interpolation between sampling points and extrapolation beyond the last quantifiable value by means of
22 the apparent terminal disposition rate constant. Steady-state levels were approximated by building time-
23 staggered superposition cascades of the reference profiles for ten 4-weekly doses, assuming the
24 pharmacokinetics to be dose-proportional and time-invariant.

25

26 **2.10. Statistical Methods**

27 All statistical methods are identified in respective figure legends. For statistical analyses, the software GraphPad
28 Prism version 8.4.3 (686) for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com,
29 was used.

- 1 PK analyses were carried out by means of PCModfit v7.0 (2021); Copyright of Graham D. Allen, available at
- 2 <https://pcmodfit.co.uk/index.html>, accessed on 23.07.2021.
- 3

1 3. Results

2 We obtained CP donation units from Octapharma Plasma[®]'s donation centers in the US ranging from 05/2020 to
3 08/2020 to understand early in the pandemic how CP donations present themselves in terms of titer and inter-
4 donation variation. We therefore first tested 133 single donations by means of qualitative anti-SARS-CoV-2-S1
5 RBD IgG ELISA. We found a positive signal of anti-SARS-CoV-2 in 79% of CP donations, while 15% and 6%
6 of the donations exhibited borderline and negative results, respectively. The ab ratio ranged from <0.1 (limit of
7 detection, LOD) up to 16 while the mean ratio was 4.5 ± 3.6 (Fig.1a).

8 We next set out to investigate what these ELISA data mean in terms of actual virus neutralization. Therefore,
9 313 CP donations including the above sample set were analyzed by actual virus neutralization in a so-called NT
10 screening assay format (Fig 1b). We found a high variability of neutralization activity among CP donations. 25%
11 had a neutralization capacity close to or below the LOD (0-45 IU/ml). 28% had only weak a neutralization titer
12 with less than 150 IU/ml. 21% of donations had a mean titer of 223 IU/ml, representing a moderate/average
13 neutralization. The last quarter of samples had a neutralization titer above 300 IU/ml, while only a fraction of
14 10% of all donations had a neutralizing activity of at least 600 IU/ml. The maximal donation neutralization titer
15 found was 2017 IU/ml. On average all convalescent donations had a mean neutralization titer of 245 ± 302
16 IU/ml. Despite this high variability, we could verify a mean convalescent level around 200 IU/ml in other CP
17 donation cohorts (data not shown).

18 Given the reports on frequent asymptomatic to mild SARS-CoV-2 infections and the general interest on how
19 epidemiologic developments (Covid-19 infection as well as vaccination programs) in the US donor population
20 reflects in IVIG/SCIG, we investigated commercial lots derived from US plasma sources for SARS-CoV-2
21 reactivity from 11/2020 until 06/2021 by means of quantitative SARS-CoV-2 S1 RBD IgG ELISA. (Fig. 2a).
22 Pre-pandemic lots were tested negative in the ELISA excluding cross-reactivity of the assay against 'common-
23 cold' coronaviruses. Systematic investigations started in 11/2020 and first reactive lots were detected in 12/2020
24 with ELISA IgG titer ranging from 40 to 170 BAU/ml with a mean value of 100 BAU/ml. A progressive
25 reactivity increase was observed, which took up pace in the very last months of observation. A mean of SARS-
26 CoV-2 IgG titer of 1048 ± 363 BAU/ml was found in IVIG/SCIG lots produced in June 2021.

27 To substantiate this information, we further tested ELISA-positive lots in NT in the so-called potency assay
28 format meaning three independent dilution series per sample with 8 replicates per dilution, respectively (Fig. 2b).
29 This assay setup gives more reliable results per sample, while throughput is limited also being restrained to BSL-

1 3 procedures. Experimental performance of both screening and potency assay formats are summarized in Supp.
2 Fig. 1.

3 Comparable to ELISA data, first neutralizing IVIG/SCIG lots were identified in 12/2020 (mean 21 ± 16 IU/ml).
4 An exponential, yet slow increase in neutralization activities was observed subsequently (i.e. mean values in
5 02/2021: $61 \text{ IU} \pm 37 \text{ IU/ml}$; 04/2021: $107 \pm 32 \text{ IU/ml}$; 05/2021: $216 \text{ IU/ml} \pm 96 \text{ IU/ml}$ and 06/2021: 506 ± 242
6 IU/ml). The maximum NC50 measured so far was 864 IU/ml. We fitted the median SARS-CoV-2 neutralizing
7 titers by exponential growth equation fit (least squares regression without weighing, no outlier handling and
8 constraints) and found an R^2 of 0.98.

9 For comparison and as possible reference to the US plasma donor population, data adapted from CDC
10 epidemiologic surveillance on SARS-CoV-2 exposure of the total US population is referenced in Fig. 2b [2].

11 We also performed correlation of the IgG ELISA data and the NT results and found a correlation coefficient of
12 $r = 0.94$ (Pearson, two-tailed, 95% CI) with $p < 0.0001$ indicating a quantitative character of the IgG ELISA. The
13 linear regression R^2 was 0.89 (Fig. 2c).

14 Finally, we asked how currently measured final container potencies relate into steady-state plasma levels in a
15 patient receiving IVIG 10%. We deployed data from a previously published trial (EudraCT 2009-011434-10)
16 with pharmacokinetic characterization of the levels of total IgG on repeated 4-weekly IVIG dosing (median
17 dose: 27.45 g, inter-quartile range [IQR]: 20.4 to 29.1 g) in 30 patients (11 females, 19 males; 8 children,
18 4 adolescents, and 18 adults) with primary immunodeficiency syndrome (median body weight [BW]: 67.75 kg,
19 IQR: 52.4 to 75.3 kg) [40]. From the individual time courses of the untransformed IgG levels (Supp. Fig. 3a), the
20 individual baseline-adjusted IgG-gain by dose was derived assuming that the pre-dose trough levels only
21 reflected residuals from preceding dosing whilst endogenous levels were assumed to be negligible (Supp.
22 Fig. 3b). The respective curves were then normalized by dose per kg-BW to allow pooling across subjects; the
23 time courses of the median, 25th and 75th percentiles (P25/P75) of these baseline-adjusted dose-normalized levels
24 were retained as reference profiles (Supp. Fig. 3c). These reference profiles were then expanded to infinity and
25 used to approximate the time courses of the IgG levels on repeated 4-weekly dosing by staggered superposition
26 assuming dose-proportional and time-invariant, i.e. linear pharmacokinetics (Supp. Fig. 3d). This was then
27 repeated for different doses. With the median dose of the original experiment (27.45 g per 67.75 kg, i.e. 0.406
28 g/kg), such approximations based on the median reference profile yield an average (C_{av}) level in steady-state of
29 9.6 mg/ml surrounded by a fluctuation from a trough (C_{min}) of 7.4 mg/ml to a peak (C_{max}) of 14.8 mg/ml).

1 Next, we set out to transfer the measured SARS-CoV-2 neutralization potency in final containers to total IgG
2 plasma levels – assuming no ab-specific elimination process. We arbitrarily chose a recent, yet average final
3 container concentration to perform the superposition (i.e. 05/2021: 216 ± 96 IU/ml per 100 mg/ml). The resulting
4 potential titers in plasma of PID patients of the course of 10 superpositioned dosings is shown in Figure 3. With
5 a neutralization potency of 2.16 IU/mg, dosing of the original experiment (i.e. 4-weekly doses of 0.406 g/kg)
6 could be approximated to yield an average steady-state level (C_{av}) of 20.2 IU/ml (C_{min} : 16.0; C_{max} : 32.0 IU/ml)
7 (Table 1). For the same dosage but using the P25 reference profile, C_{av} , C_{min} , and C_{max} in steady-state would be
8 15.15, 11.34, and 25.1 IU/ml, respectively; for the P75 reference profile, 21.80, 15.87, and 35.61 IU/ml,
9 respectively.

10

1 4. Discussion

2 Immunodeficient patients not amenable to efficient response to vaccination rely on prophylaxis measures not
3 only against SARS-CoV-2 infection but also other circulating pathogens. Plasma-derived Ig is the standard of
4 care to substitute the ab repertoire in these patients with IVIG/SCIG manufactured from thousands of donations
5 per batch. In the light of the pandemic, these immunodeficient patients and their health care professionals are
6 interested in if and when a potential protection from severe infection or even SARS-CoV-2 infection might be
7 achieved.

8 While neutralizing plasma ab levels remain to be validated as a correlate of protection in clinical studies, here we
9 reported a rapid increase of SARS-CoV-2 neutralization potency in Octapharma®'s IVIG/SCIG final containers
10 by means of ELISA and microneutralization testing using SARS-CoV-2 WT (D614G). We found a very good
11 correlation of the ELISA data to the actual virus neutralization data, which is in line with previously published
12 observations on the performance of the Euroimmun IgG ELISA suggesting it to be a suitable surrogate to
13 perform donation screening and even semi-quantitatively approximate SARS-CoV-2 neutralization potency in
14 IVIG/SCIG matrices [41–43].

15 First positive IVIG/SCIG final containers were detected in 12/2020, produced partly from pre-pandemic plasma
16 and donations obtained in August 2020 (minimal production lead time: 5 months). The reported Covid-19
17 prevalence in July 2020 was about 1% [2], while recent reports suggest a 4.8 fold higher seroprevalence during
18 the first wave of the pandemic [44]. In contrast to a previous report, we could not detect a relevant cross-
19 neutralizing activity in pre-pandemic batches of IVIG/SCIG [45].

20 The observed increase IVIG/SCIG final container neutralization titers fits well to the forecast by Farcet et al.,
21 who predicted for 02/2021-05/2021: 53 / 71 / 98 / 164 IU/ml, respectively; measured 61 / 71 / 106 and 216 IU/ml
22 on average [32]. Not factored in in this prediction was the successful onset of the vaccination campaign in the
23 US, which had an almost exponential increase with regards to “first-dose in” from 01/2021 until 05/2021 [2].
24 The later potentially being responsible for the ongoing exponential increase in 06/2021.

25 Given that production of Octapharma®'s IVIG/SCIG endures at least 5 months from donation until filling and
26 with the reported exponential increase in serologically relevant exposure of the US total population from the first
27 half-year in 2021 (inferring this to be an acceptable correlate of our donor population), suggests a further
28 increase of neutralization capacities at least until fall 2021, while the exponential increase will likely see an
29 inflection point and turn into a saturation phase. On which level SARS-CoV-2 neutralization titers will plateau

1 and how stable this plateau will be overtime surely depends on many factors: e.g. (i) the increase in vaccinees
2 over-taking the CP donors in numbers might potentially lead to a different “on-average”, potentially more
3 consistent contribution per plasma donation [46–48]. Our assessment on a small subset of convalescent donors (n
4 = 313) showed that there has been a marked spread in reactivity between the donations. Almost half of
5 convalescent donations was non- or low reactive. This was more pronounced as in earlier reports, with almost a
6 quarter of all donors as low/no responders [49]. In our analysis, only about 10% of the investigated convalescent
7 single donations could meet actual titer demands under revised emergency use authorization (EUA) issued by
8 FDA for CP treatment in acute Covid-19 infection [7]. However, these rare high-titer donations eventually drive
9 the titer plasma pools. (ii) Furthermore, first case reports have been described where convalescent patients
10 received vaccinations with mRNA vaccines boosting their neutralization titers at least 20x compared to their
11 previous levels [50, 51]. These booster effects will likely impact potencies in individual plasma donations and
12 subsequently in the IVIG/SCIG final containers. (iii) Even more interesting will be to see on which level anti-
13 SARS-CoV-2 antibodies prevail on the long run, given waning of neutralization titers [52] and loss of sterile
14 immunity on mucosal surface of donors potentially allowing mild natural SARS-CoV-2 re-infection [53] and
15 subsequent “natural” titer boosts. A model for this could be the detectable levels of seasonal coronaviruses in
16 IVIG/SCIG formulations [32, 54]. Additionally, depending on public health policies, repeated boost vaccinations
17 may also drive long-term ab levels against SARS-CoV-2 [55].
18 (iv) Aside the insecurity on the quality of individual donations, we must emphasize that the manufacture of
19 IVIG/SCIG involves also the pooling of intermediates and donations over a collection time span of up to one
20 year, which has the potential to average out epidemiologic trends, such as vaccination levels.

21

22 While final container neutralization potencies against WT (D614G) SARS-CoV-2 are strongly increasing, it is of
23 interest how these could translate into steady-state trough levels in a patient, which is one possible, yet not
24 validated correlate of immune protection. Approximations of the steady-state trough levels based on a 4-weekly
25 IVIG dosing by superposition of the median baseline-adjusted reference curve - derived from actual trial data
26 [40] - indicate that doses of 0.4 g/kg yield a trough level of about 7.40 mg/ml IgG (trough levels at P25/P75 were
27 5.25 and 7.25 mg/ml, respectively). These superpositioned values correspond well to previously published IVIG
28 steady state plasma levels [56].

29 As a basis for our calculation, the median anti-SARS-CoV-2 neutralizing potency of 10% IVIG in May 2021
30 was chosen with 216 IU/ml or 216 IU/100 mg = 2.16 IU/mg. The approximated trough levels would

1 correspondingly be about 16.0 IU/ml (P25: 11.3 IU/ml, and P75: 15.9 IU/ml) – provided no underlying idiotype-
2 specific elimination processes. This span of the patient PK-superposed reference profiles is comparably low. The
3 variation in-between SARS-CoV-2 neutralization in 05/2021 was much larger with a coefficient of variation of
4 44%. Likewise, the spans between the investigated time periods has more impact on the theoretical plasma
5 trough levels than variation within PK reference profiles in [40]: a final container with the maximum
6 neutralization potency measured (06/2021: 864 IU/ml) would result in 64 IU/ml plasma trough levels, while the
7 average final container potency in 02/2021 (61 IU/ml in final container) would lead to 4.5 IU/ml.

8 To put these potential plasmatic NC50 values into context, Khoury and Cromer have recently published meta-
9 analyses providing a first estimate of a protective level against SARS-CoV-2 infection. They estimated a 50%
10 protection level from symptomatic SARS-CoV-2 infection to be around 20% of the CP titer (54 IU/ml; 95%CI:
11 30-96 IU/ml) [48]. Since effects of cellular immunity induced by vaccination might confound this suggested
12 protective measure - and patients receiving IVIG/SCIG treatment are immunologically naïve or lack a potent
13 cellular immunity - especially for full protection, the protective threshold could be well higher. Also it has to be
14 kept in mind that neutralizing plasma ab have so far not been validated as a correlate of protection, at all. In this
15 light, the calculated anti-SARS-CoV-2 trough plasma levels (based on the average final container potency from
16 05/2021: 16 IU/ml) are interpreted as sub-protective levels against infection (96 IU/ml; upper 95% CI limit).

17 Although the epidemiological comparison to the US total population is a sub-optimal - yet well available -
18 indicator of vaccination and Covid-19 convalescence for the actual donor population [2], and given what we
19 observe in individual IVIG lots, an increase in anti-SARS-CoV-2 titer to meet trough levels suggested by
20 Khoury and Cromer et al. seems possible. The current maximum NC50 value measured in IVIG/SCIG was
21 864 IU/ml in 06/2021 and most seroconversions have occurred only recently (keeping in mind the > 5 months
22 lead time of IVIG/SCIG production). As discussed earlier, vaccination of convalescent donors also has been
23 described to boost immunity, rendering individual plasma contributions potentially higher in titer than early in
24 the pandemic [50, 51]. However, production of IVIG/SCIG involves intermediate production and pooling, which
25 bears the potential to average plasma donation periods and hence not strictly following donors' epidemiology.

26 While it is prudent to speculate on the ongoing increase of titers in IVIG/SCIG final containers, the long-term
27 perspective of anti SARS-CoV-2 ab levels in IVIG/SCIG remains elusive and is surely impacted by e.g. long-
28 term (sterile) immunity of the individual, public health policies (booster immunizations), and circulating SARS-
29 CoV-2 variants. Furthermore, the required anti-SARS-CoV-2 titer in IVIG/SCIG has to be carefully interpreted
30 as many uncertainties could factor in: e.g., (i) ab levels without the back-up of cellular immunity have so far not
31 been shown as a correlate of protection in immunocompromised patients. Only from recombinant monoclonal

1 therapy there are first suggestive information that antibodies can protect against infection [19]. (ii) The actual PK
2 of anti-SARS-CoV-2 antibodies could follow other than on-average IVIG PK profiles resulting in different
3 plasma trough levels. Here, clinical studies in IVIG/SCIG receiving patient-cohorts are needed to provide
4 information on plasma IgG levels in these patients and correlate those with the potencies found in the infused
5 formulations. A further limitation is that here presented data was generated using the D614G variant close to
6 Wuhan wildtype strain, while the pandemic is currently driven by SARS-CoV-2 variants of concern and -
7 interest. However, polyclonality of IVIG/SCIG could render a complete neutralization evasion of variants less
8 likely as compared to monoclonal therapies, while for CP (from one donor, respectively) immune escape of
9 variants of concern from neutralization has been shown of approximately 15x, underscoring the general notion
10 that optimal neutralization/protection is achieved against the isolate that caused the immune response [57]. In a
11 passive immunization setting with IVIG/SCIG, this means not only trailing the epidemiology of donors in terms
12 of neutralizing titer but also in terms of quality, meaning which variants will be neutralized best.

13

1 5. Conclusion

2 Here, we report the onset of SARS-CoV-2 neutralizing antibodies in IVIG/SCIG final containers from 12/2020
3 with an exponential increase in neutralizing titers. The average values found were 02/2021: 61 IU \pm 37 IU/ml;
4 04/2021: 107 \pm 32 IU/ml; 05/2021: 216 IU/ml \pm 96 IU/ml and 06/2021: 506 \pm 242 IU/ml). The maximum NC50
5 measured so far was 864 IU/ml.

6 Furthermore, we arbitrarily chose a recent, yet average final container concentration to convert neutralization
7 potencies of IVIG/SCIG final containers to possible trough-plasma levels in steady-state. Trough-levels of
8 16 IU/ml were projected based on the average neutralizing titer in 05/2021. While this value seems low, the
9 highest detected final container potency of 864 IU/ml (maximum in latest 06/2021 time-point) would result in a
10 theoretical trough level of 64 IU/ml.

11 However, which plasma levels are needed for protection against SARS-CoV-2 infection of immune-
12 compromised patients is currently under discussion. A first estimate postulates 30-96 IU/ml with several caveats
13 and limitations. It is therefore a matter of further clinical investigations to verify and pinpoint a protective ab-
14 level in immunocompromised patients – without (or with reduced) the background of cellular immunity.

15 Despite a considerable lot-to-lot variability, a further increase based on the epidemiologic developments in the
16 US plasma donor population seems plausible at least until fall 2021.

1 **Declarations**

2 **Funding**

3 Octapharma® Pharmazeutika Produktionsgesellschaft m.b.H., Austria and Octapharma Biopharmaceuticals®
4 GmbH, Germany and Octapharma Plasma® Inc., USA were the funding source. Octapharma Plasma® Inc. was
5 involved in plasma donation collection. Octapharma® Pharmazeutika Produktionsgesellschaft m.b.H. and
6 Octapharma Biopharmaceuticals® GmbH were involved in analysis and data generation. Octapharma®
7 Pharmazeutika Produktionsgesellschaft m.b.H. covered all costs incurred for the present publication.
8 ACPS-Network GmbH was paid for their PK analysis services by Octapharma Biopharmaceuticals® GmbH.

9

10 **Conflicts of interest**

11 AV, CCS, DK, JR and TS are employed by companies part of the Octapharma® group. CDM is owner and CEO
12 of ACPS and received payment by Octapharma® for the services involved in the preparation of this study.

13

14 **Trademarks**

15 Octagam®, Cutaquig® and Panzyga® are trademarks of the Octapharma® group.

16

17 **Availability of data and material**

18 Material that is still in existence and owned by Octapharma® can be made available in principle for research
19 purposes by non-profit organizations upon justified request.

20 WHO international standard was obtained from NIBSC, Potters Bar, UK (see materials and methods section) [1].

21 All data except epidemiologic data on seroconversion generated or analyzed during this study are included in this
22 published article and its supplementary information files.

23 Epidemiologic data on United States status of vaccination and Covid-19 cumulated cases were obtained from

24 CDC Data Tracker website [2].

25

1 **Code availability**

2 Not applicable

3

4 **Ethics approval**

5 Not applicable

6

7 **Consent to participate**

8 All plasma donations analyzed in this study were obtained after informed consent of the donors. Plasma products
9 analyzed within this study were produced from material donated after informed consent for the purpose of
10 producing pharmaceutical products.

11

12 **Consent to publish**

13 Not applicable

14

15 **Authors' contributions**

16 All authors contributed to the study conception and design. Material preparation, data collection and analysis
17 were performed by Andreas Volk, Caroline Covini-Souris, Christian de Mey and Denis Kuehnel. The first draft
18 of the manuscript was written by Andreas Volk and all authors commented on previous versions of the
19 manuscript. All authors read and approved the final manuscript.

20

21 **Acknowledgements**

22 Special thanks go to Gabriele Hoch and Lisa Oberland for virus and cell culture as well as the staff of Virus and
23 Prion Validation at Octapharma® for provision of expertise and support.

1 The authors cordially thank Sonja Hoeller and Bernhard Rohrbacher (Global Medical and Scientific Affairs,
2 Octapharma® Pharmazeutika Produktionsgesellschaft m.b.H, Austria) for their input and critically reviewing the
3 manuscript.

4 We thank Monica Byrd (Octapharma Plasma® Inc., USA), Sabine Simlinger and Michael Szkutta (Octapharma®
5 Pharmazeutika Produktionsgesellschaft m.b.H, Austria) for the provision of plasma donations as well as
6 anonymized, information on non-personal records and data.

7 We thank the CoVIg Alliance for collaboration and exchange.

8

1 **References**

- 2 1. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard
3 for anti-SARS-CoV-2 immunoglobulin. *Lancet*. 2021;397:1347–8. doi:10.1016/S0140-6736(21)00527-4.
- 4 2. Centers for Disease Control and Prevention. CDC Covid Data Tracker. 2021. [https://covid.cdc.gov/covid-](https://covid.cdc.gov/covid-data-tracker/#national-lab)
5 data-tracker/#national-lab. Accessed 2 Jun 2021.
- 6 3. Nobel Media AB 2021. The Nobel Prize in Physiology or Medicine 1901. 1901.
7 <https://www.nobelprize.org/prizes/medicine/1901/summary/>. Accessed 6 Jun 2021.
- 8 4. Brown BL, McCullough J. Treatment for emerging viruses: CP and COVID-19. *Transfus Apher Sci*.
9 2020;59:102790. doi:10.1016/j.transci.2020.102790.
- 10 5. Focosi D, Tuccori M, Franchini M. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins
11 (Hyperimmune Serum) for Passive Immunization in COVID-19. *Life (Basel)* 2021.
12 doi:10.3390/life11020144.
- 13 6. Chen L, Xiong J, Bao L, Shi Y. CP as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;20:398–
14 400. doi:10.1016/S1473-3099(20)30141-9.
- 15 7. Food and Drug Administration. Emergency Use Authorization of Covid-19 CP.
- 16 8. Peng HT, Rhind SG, Beckett A. CP for the Prevention and Treatment of COVID-19: A Systematic Review
17 and Quantitative Analysis. *JMIR Public Health Surveill*. 2021;7:e25500. doi:10.2196/25500.
- 18 9. Franchini M, Glingani C, Morandi M, Corghi G, Cerzosimo S, Beduzzi G, et al. Safety and Efficacy of CP
19 in Elderly COVID-19 Patients: The RESCUE Trial. *Mayo Clin Proc Innov Qual Outcomes*. 2021;5:403–12.
20 doi:10.1016/j.mayocpiqo.2021.01.010.
- 21 10. Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. Effects
22 of potent neutralizing antibodies from CP in patients hospitalized for severe SARS-CoV-2 infection. *Nat*
23 *Commun*. 2021;12:3189. doi:10.1080/01621459.1999.10474144.
- 24 11. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of CP
25 Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. *Mayo Clin*
26 *Proc*. 2021;96:1262–75. doi:10.1016/j.mayoep.2021.02.008.
- 27 12. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. CP Antibody Levels and the
28 Risk of Death from Covid-19. *N Engl J Med*. 2021;384:1015–27. doi:10.1056/NEJMoa2031893.
- 29 13. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma
30 Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med*. 2021;384:610–8.
31 doi:10.1056/NEJMoa2033700.
- 32 14. Simonovich VA, Burgos Prax LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A Randomized
33 Trial of CP in Covid-19 Severe Pneumonia. *N Engl J Med*. 2021;384:619–29.
34 doi:10.1056/NEJMoa2031304.
- 35 15. Haagmans BL, Noack D, Okba NMA, Li W, Wang C, Bestebroer T, et al. SARS-CoV-2 neutralizing
36 human antibodies protect against lower respiratory tract disease in a hamster model. *J Infect Dis*.
37 2020;223:2020–8. doi:10.1101/2020.08.24.264630.
- 38 16. Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, et al. In vivo monoclonal antibody efficacy
39 against SARS-CoV-2 variant strains. *Nature* 2021. doi:10.1038/s41586-021-03720-y.
- 40 17. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection
41 against SARS-CoV-2 in rhesus macaques. *Nature*. 2021;590:630–4. doi:10.1038/s41586-020-2456-9.
- 42 18. Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, et al. Effect of Bamlanivimab vs
43 Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living
44 Facilities: A Randomized Clinical Trial. *JAMA* 2021. doi:10.1001/jama.2021.8828.

- 1 19. Alexandra Bowie. Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used
2 as Passive Vaccine to Prevent COVID-19. TARRYTOWN, N.Y., USA; January 26, 2021.
- 3 20. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech
4 COVID-19 Vaccine in Patients with Inborn Errors of Immunity. *J Allergy Clin Immunol* 2021.
5 doi:10.1016/j.jaci.2021.05.029.
- 6 21. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, et al. Robust
7 Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. *J Clin Immunol*
8 2021. doi:10.1007/s10875-021-01046-y.
- 9 22. Tougeron D, Hentzien M, Seitz-Polski B, Bani-Sadr F, Bourhis J, Ducreux M, et al. Severe acute
10 respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of
11 a French oncology intergroup (GCO, TNCD, UNICANCER). *Eur J Cancer*. 2021;150:232–9.
12 doi:10.1016/j.ejca.2021.03.030.
- 13 23. Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. *Nat Rev Immunol*. 2013;13:519–33.
14 doi:10.1038/nri3466.
- 15 24. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients
16 with inborn errors of immunity: An international study. *J Allergy Clin Immunol*. 2021;147:520–31.
17 doi:10.1016/j.jaci.2020.09.010.
- 18 25. Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Ahanchian H, et al. Impact of SARS-
19 CoV-2 Pandemic on Patients with Primary Immunodeficiency. *J Clin Immunol*. 2021;41:345–55.
20 doi:10.1007/s10875-020-00928-x.
- 21 26. Dwyer JM. Immunoglobulins in autoimmunity: history and mechanisms of action. *Clin Exp Rheumatol*.
22 1996;14 Suppl 15:S3-7.
- 23 27. Ramesh S, Schwartz SA. Therapeutic uses of intravenous immunoglobulin (IVIG) in children. *Pediatr Rev*.
24 1995;16:403-10; quiz 410.
- 25 28. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. *Pediatr*
26 *Infect Dis J*. 1997;16:696–707. doi:10.1097/00006454-199707000-00012.
- 27 29. Radomski KU, Lattner G, Schmidt T, Römisch J. Pathogen Safety of a New Intravenous Immune Globulin
28 10% Liquid. *BioDrugs*. 2017;31:125–34. doi:10.1007/s40259-017-0212-y.
- 29 30. Frenzel W, Wietek S, Svae T-E, Debes A, Svorc D. Tolerability and safety of Octagam® (IVIG): a post-
30 authorization safety analysis of four non-interventional phase IV trials. *Int J Clin Pharmacol Ther*.
31 2016;54:847–55. doi:10.5414/CP202782.
- 32 31. Karbiener M, Farcet MR, Ilk R, Schreiner J, Lenart J, Powers N, et al. Longitudinal analysis of SARS-CoV-
33 2 antibodies in 8000 U.S. first-time CP donations. *Transfusion*. 2021;61:1141–7. doi:10.1111/trf.16291.
- 34 32. Farcet MR, Karbiener M, Schwaiger J, Ilk R, Kreil TR. Rapidly Increasing SARS-CoV-2 Neutralization by
35 Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic. *J Infect Dis*
36 2021. doi:10.1093/infdis/jiab142.
- 37 33. Pisani G, Cristiano K, Simeoni M, Martina A, Pati I, Carocci A, et al. Detection of antibodies against
38 SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins
39 produced from plasma collected in Italy during the pandemic. *Blood Transfus* 2021.
40 doi:10.2450/2021.0055-21.
- 41 34. Vandeberg P, Cruz M, Diez JM, Merritt WK, Santos B, Trukawinski S, et al. Brief report: Production of
42 anti-SARS-CoV-2 hyperimmune globulin from CP. *Transfusion* 2021. doi:10.1111/trf.16378.
- 43 35. Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E, et al. Production of hyperimmune anti-SARS-CoV-2
44 intravenous immunoglobulin from pooled COVID-19 CP. *Immunotherapy*. 2021;13:397–407.
45 doi:10.2217/imt-2020-0263.


- 1 36. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of
2 hospitalized patients with COVID-2019. *Nature*. 2020;581:465–9. doi:10.1016/S1473-3099(15)70090-3.
- 3 37. Gauger PC, Vincent AL. Serum virus neutralization assay for detection and quantitation of serum-
4 neutralizing antibodies to influenza A virus in swine. *Methods Mol Biol*. 2014;1161:313–24.
5 doi:10.1007/978-1-4939-0758-8_26.
- 6 38. Orlinger KK, Holzer GW, Schwaiger J, Mayrhofer J, Schmid K, Kistner O, et al. An inactivated West Nile
7 Virus vaccine derived from a chemically synthesized cDNA system. *Vaccine*. 2010;28:3318–24.
8 doi:10.1016/j.vaccine.2010.02.092.
- 9 39. Luigi Cavalli-Sforza. *Grundzüge biologische-medizinischer Statistik*. 3rd ed. Stuttgart: Gustav Fischer
10 Verlag; 1972.
- 11 40. Melamed IR, Borte M, Trawnicek L, Kobayashi A-L, Kobayashi RH, Knutsen A, et al. Pharmacokinetics of
12 a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases:
13 Analysis of a phase III, multicentre, prospective, open-label study. *Eur J Pharm Sci*. 2018;118:80–6.
14 doi:10.1016/j.ejps.2018.03.007.
- 15 41. Walker GJ, Naing Z, Ospina Stella A, Yeang M, Caguicla J, Ramachandran V, et al. SARS Coronavirus-2
16 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme
17 Immunoassays. *Viruses* 2021. doi:10.3390/v13020247.
- 18 42. Rychert J, Couturier MR, Elgort M, Lozier BK, La'ulu S, Genzen JR, et al. Evaluation of 3 SARS-CoV-2
19 IgG Antibody Assays and Correlation with Neutralizing Antibodies. *J Appl Lab Med*. 2021;6:614–24.
20 doi:10.1093/jalm/jfaa188.
- 21 43. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al. Performance of
22 six SARS-CoV-2 immunoassays in comparison with microneutralisation. *J Clin Virol*. 2020;129:104512.
23 doi:10.1016/j.jcv.2020.104512.
- 24 44. Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, et al. Undiagnosed SARS-
25 CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. *Sci Transl
26 Med* 2021. doi:10.1126/scitranslmed.abh3826.
- 27 45. Díez J-M, Romero C, Vergara-Alert J, Belló-Perez M, Rodon J, Honrubia JM, et al. Cross-neutralization
28 activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins 2020.
29 doi:10.1101/2020.06.19.160879.
- 30 46. Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine
31 against SARS-CoV-2 - Preliminary Report. *N Engl J Med*. 2020;383:1920–31.
32 doi:10.1056/NEJMoa2022483.
- 33 47. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the
34 BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
- 35 48. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels
36 are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021.
37 doi:10.1198/jcgs.2009.07130.
- 38 49. Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 CP
39 donors: optimal donors and timing of donation. *Transfusion* 2020. doi:10.1111/trf.15918.
- 40 50. Vickers MA, Sariol A, Leon J, Ehlers A, Locher AV, Dubay KA, et al. Exponential increase in neutralizing
41 and spike specific antibodies following vaccination of COVID-19 CP donors. *Transfusion* 2021.
42 doi:10.1111/trf.16401.
- 43 51. Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-
44 variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* 2021.
45 doi:10.1126/science.abg9175.

- 1 52. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies
2 against SARS-CoV-2 among infected healthcare workers. *Nat Commun.* 2021;12:844. doi:10.1038/s41467-
3 021-21111-9.
- 4 53. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing
5 antibody response to SARS-CoV-2. *Sci Transl Med* 2021. doi:10.1126/scitranslmed.abd2223.
- 6 54. Díez JM, Romero C, Gajardo R. Effective presence of antibodies against common human coronavirus in
7 IgG immunoglobulin medicinal products. online: bioRxiv; 2021.
- 8 55. Kai Wu, Angela Choi, Matthew Koch, LingZhi Ma, Anna Hill, Naveen Nunna, Wenmei Huang, Judy
9 Oestreicher, Tonya Colpitts, Hamilton Bennett, Holly Legault, Yamuna Paila, Bilitiana Nestorova, Baoyu
10 Ding, Rolando Pajon, Jacqueline M Miller, Brett Leav, Andrea Carfi, Roderick McPhee, Darin K Edwards.
11 Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. medRxiv.
12 2021:Preprint.
- 13 56. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.
14 *Immunol Allergy Clin North Am.* 2008;28:803-19, ix. doi:10.1016/j.iac.2008.06.006.
- 15 57. Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from
16 neutralization by CP. *Nature.* 2021;593:142–6. doi:10.1016/j.xcrm.2021.100204.

17

18

1 Figures



2

3 Fig. 1 Characterization of CP single donations for SARS-CoV-2 reactivity by means of **a** IgG ELISA and **b**

4 microneutralization assay. **a** ELISA ratios of SARS-CoV-2 IgG are plotted. Cut off is set by ELISA kit

5 manufacturer as 1.1. Interpretation was negative if ratio is < 0.8; positive if ≥ 1.1 ; borderline if $1.1 > x > 0.8$. **b**

6 Samples are clustered into potency ranges (right) and shown as total sample set (left). For each ranked sub-


7 population the mean normalized neutralization titers \pm SD are depicted on the left y-axis and values are shown

8 above bars. The number of donations binned to each potency subset is shown at the bottom of each bar. The

9 fraction of each subset to the total sample size is indicated by blue horizontal lines and depicted on the right y-

10 axis. IU: international units

11



1

2 Fig. 2 SARS-CoV-2 reactivity and neutralization titer of IVIG/SCIG final containers from 11/2020 – 06/2021.


3 **a** Scatter plot for reactivity of 10% IVIG/SCIG final containers normalized to 10% Ig in commercial IgG

4 ELISA. Each dot represents the mean result of 8 determinations per sample counted as one measurement. The

5 week of production is plotted against ELISA signal intensity, which was normalized against the international

6 WHO standard and to 10% IgG (100 mg/ml). **b** Neutralization titer of 10% IVIG/SCIG as determined by

1 microneutralization assay is depicted on the left y-axis in IU/ml. Each dot represents the mean of triplicate
2 analysis, counting as one measurement. Neutralization over time was fitted (solid line) using non-linear fit
3 "exponential growth equation" on the median values under GraphPad Prism version 8.4.3 (686). The cumulative
4 minimal serologically relevant exposure of the total US population is depicted as dash-dotted line (right y-axis)
5 in blue. The latter were obtained from CDC Covid Data Tracker [7]. **c** Correlation analysis of ELISA (x axis)
6 and microneutralization results (y-axis). Correlation coefficient was calculated using two-tailed, Gaussian
7 distributed values at 95%CI (Pearson) under GraphPad Prism version 8.4.3 (686). BAU/ml: Binding antibody
8 units
9



1

2 Fig. 3 Approximated time courses of the neutralizing anti-SARS-CoV-2 IgG-levels (IU/ml) throughout ten 4-
3 weekly repeated doses of intravenous IgG (potency 216 IU/100 mg) dosed with the median dose of the reference
4 dataset (0.406 g/kg-BW). Data was processed using PCModfit v7.0 (2021). PK data was obtained from a
5 previously published study [40]

6

1 Table 1: Approximated steady-state trough (Cmin), peak (Cmax), and average (Cav) neutralizing SARS-COV-2

	Derived from the median reference	Derived from the P25 reference	Derived from the P75 reference
Cmin [IU/ml]	16	11	16
Cmax [IU/ml]	32	26	36
Cav [IU/ml]	20	15	22

2

3 IgG-levels were estimated through a superposition cascade with time-staggered dosing using the median, 25th

4 (P25), and 75th (P75) percentile baseline-adjusted and dose-normalized reference curves. Estimates are

5 presented for doses of 0.406 g/kg-BW, i.e. the median dose level of the reference dataset, assuming a potency of

6 216 IU per 100 mg IVIG/SCIG

7

8